4 research outputs found
Serotonin Transporter Associated Protein Complexes Are Enriched in Synaptic Vesicle Proteins and Proteins Involved in Energy Metabolism and Ion Homeostasis
The serotonin transporter (SERT)
mediates Na<sup>+</sup>-dependent high-affinity serotonin uptake and
plays a key role in regulating extracellular serotonin concentration
in the brain and periphery. To gain novel insight into SERT regulation,
we conducted a comprehensive proteomics screen to identify components
of SERT-associated protein complexes in the brain by employing three
independent approaches. In vivo SERT complexes were purified from
rat brain using an immobilized high-affinity SERT ligand, amino-methyl
citalopram. This approach was combined with GST pulldown and yeast
two-hybrid screens using N- and C-terminal cytoplasmic transporter
domains as bait. Potential SERT associated proteins detected by at
least two of the interaction methods were subjected to gene ontology
analysis resulting in the identification of functional protein clusters
that are enriched in SERT complexes. Prominent clusters include synaptic
vesicle proteins, as well as proteins involved in energy metabolism
and ion homeostasis. Using subcellular fractionation and electron
microscopy we provide further evidence that SERT is indeed associated
with synaptic vesicle fractions, and colocalizes with small vesicular
structures in axons and axon terminals. We also show that SERT is
found in close proximity to mitochondrial membranes in both, hippocampal
and neocortical regions. We propose a model of the SERT interactome,
in which SERT is distributed between different subcellular compartments
through dynamic interactions with site-specific protein complexes.
Finally, our protein interaction data suggest novel hypotheses for
the regulation of SERT activity and trafficking, which ultimately
impact on serotonergic neurotransmission and serotonin dependent brain
functions
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
ABSTRACTBiologics have revolutionized disease management in many therapeutic areas by addressing unmet medical needs and overcoming resistance to standard-of-care treatment in numerous patients. However, the development of unwanted immune responses directed against these drugs, humoral and/or cellular, can hinder their efficacy and have safety consequences with various degrees of severity. Health authorities ask that a thorough immunogenicity risk assessment be conducted during drug development to incorporate an appropriate monitoring and mitigation plan in clinical studies. With the rapid diversification and complexification of biologics, which today include modalities such as multi-domain antibodies, cell-based products, AAV delivery vectors, and nucleic acids, developers are faced with the challenge of establishing a risk assessment strategy sometimes in the absence of specific regulatory guidelines. The European Immunogenicity Platform (EIP) Open Symposium on Immunogenicity of Biopharmaceuticals and its one-day training course gives experts and newcomers across academia, industry, and regulatory agencies an opportunity to share experience and knowledge to overcome these challenges. Here, we report the discussions that took place at the EIP’s 14th Symposium, held in April 2023. The topics covered included immunogenicity monitoring and clinical relevance, non-clinical immunogenicity risk assessment, regulatory aspects of immunogenicity assessment and reporting, and the challenges associated with new modalities, which were discussed in a dedicated session
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
The determination of a tailored anti-drug antibody (ADA) testing strategy is based on the immunogenicity risk assessment to allow a correlation of ADAs with changes to pharmacokinetics, efficacy, and safety. The clinical impact of ADA formation refines the immunogenicity risk assessment and defines appropriate risk mitigation strategies. Health agencies request for high-risk biotherapeutics to extend ADA monitoring for patients that developed an ADA response to the drug until ADAs return to baseline levels. However, there is no common understanding in which cases an extension of ADA follow-up sampling beyond the end of study (EOS) defined in the clinical study protocol is required. Here, the Immunogenicity Strategy Working Group of the European Immunogenicity Platform (EIP) provides recommendations on requirements for an extension of ADA follow-up sampling in clinical studies where there is a high risk of serious consequences from ADAs. The importance of ADA evaluation during a treatment-free period is recognized but the decision whether to extend ADA monitoring at a predefined EOS should be based on evaluation of ADA data in the context of corresponding clinical signals. If the clinical data set shows that safety consequences are minor, mitigated, or resolved, further ADA monitoring may not be required despite potentially detectable ADAs above baseline. Extended ADA monitoring should be centered on individual patient benefit